or Try an Advanced Search...

    Technical Analysis for BHC - Bausch Health Companies Inc.

    Grade Last Price % Change Price Change
    B 11.450 -0.26% -0.030
    BHC closed up 0.26 percent on Wednesday, November 20, 2024, on 43 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Down
    Historical BHC trend table...
    Date Alert Name Type % Chg
    Oversold Stochastic Weakness -0.26%
    Stochastic Reached Oversold Weakness 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Gapped Down Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    New Downtrend Bearish -2.72%
    Narrow Range Bar Range Contraction -2.72%
    Gapped Down Weakness -2.72%
    Fell Below 20 DMA Bearish -4.42%
    NR7 Range Contraction -7.14%
    Older End-of-Day Signals for BHC ...

       Recent Intraday Alerts

    Alert Time
    50 DMA Support about 1 hour ago
    Down 1% about 1 hour ago
    Fell Below Previous Day's Low about 1 hour ago
    Up 2% about 22 hours ago
    Rose Above Previous Day's High about 23 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    BHC Chart by TradingView
    Basic chart:

    Profile

    Bausch Health Companies Inc. Description

    Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Health S&P/Tsx 60 Index Medicine Pharma Pharmaceutical Biotechnology Pharmaceuticals Pharmaceutical Products Laser Medical Devices Atopic Dermatitis Contact Lens Psoriasis Ulcer Ulcerative Colitis Aes Dermatology Specialty Drugs Acne Actinic Keratosis Colitis Hair Removal Irritable Bowel Syndrome Keratosis Over The Counter Products

    Is BHC a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 18 US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug
    Nov 18 Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis
    Nov 18 PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS
    Nov 6 Are Medical Stocks Lagging Bausch Health (BHC) This Year?
    Nov 4 Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term
    Nov 1 Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales
    Oct 31 Bausch Health Companies Inc (BHC) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
    Oct 31 Compared to Estimates, Bausch (BHC) Q3 Earnings: A Look at Key Metrics
    Oct 31 Bausch Health (BHC) Beats Q3 Earnings and Revenue Estimates
    Oct 30 Bausch: Q3 Earnings Snapshot
    See more BHC news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 15.43
    52 Week Low 5.45
    Average Volume 366,196
    200-Day Moving Average 10.552
    50-Day Moving Average 11.379
    20-Day Moving Average 12.287
    10-Day Moving Average 12.316
    Average True Range 0.412
    RSI (14) 43.18
    ADX 30.38
    +DI 25.095
    -DI 30.952
    Chandelier Exit (Long, 3 ATRs) 12.506
    Chandelier Exit (Short, 3 ATRs) 12.315
    Upper Bollinger Bands 13.904
    Lower Bollinger Band 10.669
    Percent B (%b) 0.25
    BandWidth 26.328
    MACD Line 0.153
    MACD Signal Line 0.389
    MACD Histogram -0.236
    Fundamentals Value
    Market Cap 4.08 Billion
    Num Shares 355 Million
    EPS -2.61
    Price-to-Earnings (P/E) Ratio -4.40
    Price-to-Sales 0.84
    Price-to-Book 11.59
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 11.915
    Resistance 3 (R3) 11.940 11.820 11.843
    Resistance 2 (R2) 11.820 11.709 11.808 11.818
    Resistance 1 (R1) 11.650 11.641 11.735 11.625 11.794
    Pivot Point 11.530 11.530 11.573 11.518 11.530
    Support 1 (S1) 11.360 11.419 11.445 11.335 11.166
    Support 2 (S2) 11.240 11.351 11.228 11.142
    Support 3 (S3) 11.070 11.240 11.118
    Support 4 (S4) 11.045